NCT04083430

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells

Detailed description

CD: cluster of differentiation YF: yellow fever

Conditions

• Healthy
• Cytotoxicity
• Yellow Fever Vaccination Reaction

Interventions

Type	Name	Description
DRUG	Yellow Fever Vaccine	STAMARIL, powder and solvent for suspension for injection in pre-filled syringe. After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU. Powder and solvent for suspension for injection. Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.

Timeline

• Start date: 2019-10-08
• Primary completion: 2025-02-15
• Completion: 2025-12-15
• First posted: 2019-09-10
• Last updated: 2025-03-27

Locations

1 site across 1 country: Denmark